ArticleCurrent computer-aided drug design2026
Exploring the Mechanism of
Article in Current computer-aided drug design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- Comparative fatty acid profiling of irradiated canola varieties: insights from GC-MS metabolomics and molecular docking.RSC advances · 2026Article
- Postoperative Complications After Lung Cancer Resection in Patients with a Previous History of Head and Neck Cancer.Cancers · 2026Article
- GC-MS Analyses and Bioactivity Evaluation of Origanum minutiflorum Essential Oil: Antioxidant, Antibacterial, Genotoxicity, and Molecular Docking Studies.Chemistry & biodiversity · 2026Article
- Comparative Phytochemical and Antiviral Characteristics ofPlants (Basel, Switzerland) · 2026Article
- CLC-Pred Synergy: Web Application for Predicting Pairwise Drug Combinations with Synergistic Activity Against NCI60 Cancer Cell Lines.International journal of molecular sciences · 2026Article
- Comparative evaluation of CNN models for nasopharyngeal carcinoma classification on pathology data.Scientific reports · 2026Article
- High-fidelity machine learning models for predicting antibacterial effects of cerium oxide nanoparticles across bacterial strains.Discover nano · 2026Article
- Beyond cytotoxicity: molecular mechanisms of natural products as multi-targeting modulators and chemo-sensitizers in oncology.Frontiers in pharmacology · 2026Review
- Advanced QSPR modeling of profens using machine learning and molecular descriptors for NSAID analysis.Scientific reports · 2025Article
- A graph-based computational approach for modeling physicochemical properties in drug design.Scientific reports · 2025Article
- Targeting adipocyte differentiation with CRT0066101: activation of AMPK signaling in 3T3-L1 cells.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCentipeda minima (CM) is a traditional Chinese herbal medicine used for the treatment of sinusitis and rhinitis, and it possesses anti-cancer properties. However, the mechanism of CM in the treatment of nasopharyngeal carcinoma (NPC) remains unclear.
objectiveThis study aimed to explore the mechanism of CM in the treatment of NPC using a network pharmacology approach.
methodsThe active components and targets of CM and NPC were screened using TCMSP, SwissTarget, and GeneCards database. The association between CM components and NPC targets or pathways was analyzed using String, Cytoscape 3.9.1, David 6.7, and AutoDock Vina. The Sangerbox platform was used to conduct differential expression and Kaplan-Meier survival analysis of core genes. RESULTS AND DISCUSSION: We identified 17 active compounds of CM and 146 corresponding targeted proteins in NPC. These targets may modulate pathways in cancer, PI3K-Akt, apoptosis, prolactin, relaxin, and TNF signaling. The top 5 core genes of the PPI network were found to be AKT1, STAT3, CASP3, EGFR, and SRC, which may be the main targets of CM in treating NPC. Molecular docking confirmed the binding energies of quercetin with CASP3, 8-Hydroxy-9,10-diisobutyryloxythymol with AKT1, and plenolin with AKT1, which were particularly low, suggesting robust and stable interactions. The expression levels of AKT1, CASP3, EGFR, SRC, MMP9, PTGS2 are significantly higher in head and neck squamous cell carcinoma (HNSC) samples compared to normal samples. In addition, the hub genes could predict the prognosis of HNSC as the Kaplan-Meier survival curve showed that patients with lower expressions of AKT1, EGFR, SRC, CCND1, PPARG had better overall survival.
conclusionBy conducting a network pharmacology approach, we revealed the main ingredients, key targets, and regulatory pathways of
Indexed as
Identifiers
39411942What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.